Navigation Links
Researchers find gene that turns up effect of chemotherapy
Date:1/29/2013

Chemotherapy is one of the most common treatments for cancer patients. However, many patients suffer from serious side-effects and a large proportion does not respond to the treatment. Researchers from the Biotech Research and Innovation Centre (BRIC) and Center for Healthy Aging, University of Copenhagen, now show that the gene FBH1 helps turn up the effect of chemotherapy.

"Our results show that the gene FBH1 is crucial in order for some chemotherapeutics to become active in the body and kill the cancer cells. If we can find a feasible method to increase the activity of the gene, we can use our cells' own resources to improve cancer treatment, says associate professor Claus Srensen who has lead the team of researchers behind the results.

Own gene helps chemotherapy fight cancer

The researchers have used a method called RNA interference to study whether some of the genes in our DNA are important for cancer cells to react to certain chemotherapeutics. "By using the method to remove single genes from cancer cells and then exposing the cells to chemotherapy, we found that FBH1 is important for the effect of the chemotherapy. Actually, the presence of the gene was an absolutely requirement in order to effectively kill the cancer cells with the type of chemotherapeutics we have studied, says postdoc Kasper Fugger who has led the experimental part of the investigation.

Chemotherapy act by exposing cancer cells to a kind of extreme stress when they divide. The result is detrimental damage to the cells' DNA that cannot be repaired, causing the cells to die. The new results show that it is in fact FBH1 that contributes to the formation of DNA damage when treating with chemotherapy and this knowledge can be used to optimize cancer therapy.

Selection of patients for chemotherapy

In the last decade it has become clear that targeted treatment to individual cancer patients is crucial for an effective treatment with least possible side-effects. By assessing the presence of FBH1 in a tumour the doctors can get an indication of whether the patient will benefit from chemotherapy.

"Our results could help indicate that patients with low or no FBH1 in the cancer cells will not benefit from certain types of chemotherapy, but should be administered another type of treatment. So by using the genetic fingerprint of a tumour doctors can adjust the treatment to individual patients, says Claus Srensen.

The next step - finding the FBH1 volume knob

The next step for the research team is to investigate the presence of changes, so-called mutations in FBH1. Identifying mutations rendering cancer cells resistant to certain chemotherapeutics can be used to target the treatment even better to individual patients. Another goal for the researchers is to find a way to turn up the activity of FBH1 in cancer cells.

"Our hope is to find a method to boost the activity of the FBH1 gene in cancer cells since this will make them more sensitive to chemotherapy. Alternatively, we may find a way to simulate an effect similar to that of FBH1, which can be used as additional treatment in order to sensitise cancer cells to chemotherapy. If we achieve this, more patients will benefit from the treatment, says Kasper Fugger.


'/>"/>
Contact: Associate professor Claus Srensen
claus.storgaard@bric.ku.dk
45-31-61-98-48
University of Copenhagen
Source:Eurekalert

Related medicine news :

1. Israeli researchers to participate in European Commission flagship
2. Tumor cells engineer acidity to drive cell invasion, Moffitt Cancer Center researchers say
3. Researchers say its time to treat anemia seriously
4. Rush researchers studying stem cell therapy to repair damaged knee cartilage
5. Researchers discover new mutations driving malignant melanoma
6. CDC Researchers Spot Increase in New Stomach Bug Strain
7. Researchers prevent cancer spread by blocking tissue scarring
8. Researchers uncover genes role in rheumatoid arthritis, findings pave way for new treatments
9. New drug improves survival in multiple myeloma relapse, Moffitt Cancer Center researchers say
10. Researchers discover promising prognostic marker for aggressive breast cancer
11. Researchers design a new imaging technique for identifying the age and sex of a corpse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family ... next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. ... 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Apple Rehab ... services, staged a mock evacuation of the facility as part of a disaster drill ... Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... DIEGO , Oct. 12, 2017 AVACEN ... recognized the company with their  2017 New Product Innovation Award ... based on extensive primary and secondary medical device market research ... Medical, through its first-to-market OTC, drug-free pain relief product, the ... unique approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
Breaking Medicine Technology: